Barrios, C. et al. Barriers in access to oncology drugs – a global crisis. Nat. Rev. Clin. Oncol. 20, 7–15 (2023).
Cherny, N. I. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat. Rev. Clin. Oncol. 19, 486–492 (2022).
Neumann, P. J., Cohen, J. T. & Ollendorf, D. A. The Right Price: A Value-Based Prescription for Drug Costs (Oxford Univ. Press, 2021).
Cai, L. et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J. Glob. Health 12, 11016 (2022).
Li, H. et al. Recent pricing negotiations on innovative medicines pilot in China: experiences, implications, and suggestions. Value Health Reg. Issues 15, 133–137 (2018).
Tang, M., Song, P. & He, J. Progress on drug pricing negotiations in China. Biosci. Trends 13, 464–468 (2019).
Zhang, Y. et al. Prices and clinical benefit of national price-negotiated anticancer medicines in China. PharmacoEconomics 40, 715–724 (2022).
Jommi, C., Armeni, P., Costa, F., Bertolani, A. & Otto, M. Implementation of value-based pricing for medicines. Clin. Ther. 42, 15–24 (2020).
Zhang, Y., Wagner, A. K. & Guan, X. Newly approved cancer drugs in China – innovation and clinical benefit. Nat. Rev. Clin. Oncol. 20, 135–136 (2023).
Yuan, J., Lu, Z. K., Xiong, X. & Jiang, B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob. Health 6, e005519 (2021).